Ordering Recommendations

Test is intended only for PSA screening purposes of patients 50 years and older.

PSA Tumor Marker [LAB3695] and Prostate Specific Antigen Screen [LAB3696] should not be ordered together.

Turnaround Time

Varies by site.

Use

Elevated in many patients with prostate cancer, as well as in some patients with prostatic hypertrophy.

Specimen Type

Blood

Collection Containers

Green (lithium heparin, gel)
Alternate Containers: Green (lithium heparin, no gel), Red (no gel), Red or Gold (Gel)

Collection Volume

2.5 mL

Minimum Collection Volume

0.6 mL

Specimen Preparation

Centrifuge and aliquot within 4 hours of collection, 1.25 mL, 0.2 mL minimum. Store in refrigerator.

Shipping Instructions

Ship at refrigerated temperature to arrive within 5 days.

Stability (from collection to initiation)

24 hours at room temperature; 5 days refrigerated; 6 months frozen.

Containers

Green (Lithium Heparin, Gel)

Alternate Containers

Green (Lithium Heparin, No Gel)

Red (No Gel)

Red or Gold (Gel)

Reference Interval

Results with different assay methods or kits cannot be used interchangeably.

Age PSA
ng/mL
40-49 y 0-2.5
50-59 y 0-3.5
60-69 y 0-4.5
70-79 y 0-6.5

This test is intended for initial prostate cancer screening. PSA values exceeding the age-specific limits are suspicious for prostate disease, but additional testing, such as prostate biopsy, is needed to diagnose prostate pathology. The American Cancer Society recommends annual examination with digital rectal examination and serum PSA beginning at age 50 and for men with a life expectancy of at least 10 years after detection of prostate cancer. For men in high-risk groups, such as African Americans or men with a first-degree relative diagnosed at a younger age, testing should begin at a younger age. It is generally recommended that information be provided to patients about the benefits and limitations of testing and treatment so they can make informed decisions.

Contraindications

Large doses of biotin (10 mg or more per day) may cause clinically significant interference in PSA tumor marker levels. If interference is suspected, it is strongly recommended that biotin is discontinued for at least one week prior to retesting.

CPT Disclaimer

The Current Procedural Terminology (CPT) Codes published in the M Health Fairview Test Directory are based on American Medical Association (AMA) guidelines and are provided for informational purposes only. CPT codes are provided only as guidance to assist clients with billing. CPT coding is the responsibility of the billing party. M Health Fairview Laboratories does not assume responsibility for billing errors due to reliance on the CPT codes listed in this Test Directory. Charges may vary due to reflexing, susceptibilities, specimen source, patient age, methodology requirements, etc..

Patient Price Inquiries

Requester Contact Information
Patient and UMP/FV Care Team Fairview Consumer Line at 612-672-1048
MRL Outreach Client DEPT-MRL-CLIENT-MANAGEMENT@Fairview.org
Research research@fairview.org

CPT Codes

CPTQtyHC HospitalPR ClinicNote
G01031300G010301G010301HC PROSTATE SPEC ANTIGEN SCREEN

Methodology

Ultrasensitive Electrochemiluminescence Immunoassay (ECLIA) 

MRL Test Build

Test Name Component Required Description Type LOINC
LAB3696     Prostate Specific Antigen Screen Orderable  
  SRC_1001 Y Blood specimen source: Prompt  
  1231002060   Prostate Specific Agn Screen Result 2857-1

Data Type / Multiple Choice Response

SRC_1001
Blood specimen source:
Arm, Left|Arm, Right|Hand, Left|Hand, Right|Blood, Capillary|Other|Peripheral Blood
Default: Peripheral Blood

Contact

For questions regarding the test code Interface Map, please contact DEPT-LAB-CLIENT-INTERFACE@fairview.org
Ordering

Ordering Recommendations

Test is intended only for PSA screening purposes of patients 50 years and older.

PSA Tumor Marker [LAB3695] and Prostate Specific Antigen Screen [LAB3696] should not be ordered together.

Turnaround Time

Varies by site.

Use

Elevated in many patients with prostate cancer, as well as in some patients with prostatic hypertrophy.
Collection & Processing

Specimen Type

Blood

Collection Containers

Green (lithium heparin, gel)
Alternate Containers: Green (lithium heparin, no gel), Red (no gel), Red or Gold (Gel)

Collection Volume

2.5 mL

Minimum Collection Volume

0.6 mL

Specimen Preparation

Centrifuge and aliquot within 4 hours of collection, 1.25 mL, 0.2 mL minimum. Store in refrigerator.

Shipping Instructions

Ship at refrigerated temperature to arrive within 5 days.

Stability (from collection to initiation)

24 hours at room temperature; 5 days refrigerated; 6 months frozen.

Containers

Containers

Green (Lithium Heparin, Gel)

Alternate Containers

Green (Lithium Heparin, No Gel)

Red (No Gel)

Red or Gold (Gel)

Result Interpretation

Reference Interval

Results with different assay methods or kits cannot be used interchangeably.

Age PSA
ng/mL
40-49 y 0-2.5
50-59 y 0-3.5
60-69 y 0-4.5
70-79 y 0-6.5

This test is intended for initial prostate cancer screening. PSA values exceeding the age-specific limits are suspicious for prostate disease, but additional testing, such as prostate biopsy, is needed to diagnose prostate pathology. The American Cancer Society recommends annual examination with digital rectal examination and serum PSA beginning at age 50 and for men with a life expectancy of at least 10 years after detection of prostate cancer. For men in high-risk groups, such as African Americans or men with a first-degree relative diagnosed at a younger age, testing should begin at a younger age. It is generally recommended that information be provided to patients about the benefits and limitations of testing and treatment so they can make informed decisions.

Contraindications

Large doses of biotin (10 mg or more per day) may cause clinically significant interference in PSA tumor marker levels. If interference is suspected, it is strongly recommended that biotin is discontinued for at least one week prior to retesting.
Administrative

CPT Disclaimer

The Current Procedural Terminology (CPT) Codes published in the M Health Fairview Test Directory are based on American Medical Association (AMA) guidelines and are provided for informational purposes only. CPT codes are provided only as guidance to assist clients with billing. CPT coding is the responsibility of the billing party. M Health Fairview Laboratories does not assume responsibility for billing errors due to reliance on the CPT codes listed in this Test Directory. Charges may vary due to reflexing, susceptibilities, specimen source, patient age, methodology requirements, etc..

Patient Price Inquiries

Requester Contact Information
Patient and UMP/FV Care Team Fairview Consumer Line at 612-672-1048
MRL Outreach Client DEPT-MRL-CLIENT-MANAGEMENT@Fairview.org
Research research@fairview.org

CPT Codes

CPTQtyHC HospitalPR ClinicNote
G01031300G010301G010301HC PROSTATE SPEC ANTIGEN SCREEN

Methodology

Ultrasensitive Electrochemiluminescence Immunoassay (ECLIA) 

Interface Mapping

MRL Test Build

Test Name Component Required Description Type LOINC
LAB3696     Prostate Specific Antigen Screen Orderable  
  SRC_1001 Y Blood specimen source: Prompt  
  1231002060   Prostate Specific Agn Screen Result 2857-1

Data Type / Multiple Choice Response

SRC_1001
Blood specimen source:
Arm, Left|Arm, Right|Hand, Left|Hand, Right|Blood, Capillary|Other|Peripheral Blood
Default: Peripheral Blood

Contact

For questions regarding the test code Interface Map, please contact DEPT-LAB-CLIENT-INTERFACE@fairview.org
Private Details

Test Detail

Processing Key

Abbreviation
PSA50
Performing Lab
CSC Mpls, Grand Itasca, Lakes, Northland, Range, UMMC East Bank
Department
Chemistry
Test Search Categories
  • Chemistry

×
Learn More Remind Me Later Dismiss